DOPA decarboxylase

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 2: Line 2:
[[image:dopa.png|thumb|left|300px|'''Dopamine Synthesis''']]'''DOPA decarboxylase''' (DDC, aromatic L-amino acid decarboxylase, tryptophan decarboxylase, 5-hydroxytryptophan decarboxylase, AAAD) ([[EC Number|EC]] 4.1.1.28) is an approximately 104 kDa protein that belongs to the '''aspartate aminotransferase family''' (fold type 1) of '''[http://en.wikipedia.org/wiki/Pyridoxal_phosphate ''PLP'']-dependent''' (vitamin B6-dependent) enzymes. The catalytically active form of the enzyme exists as a homodimer, typical of this class of enzymes.<ref name="schneider">PMID:10673430 </ref> The homodimeric form of the enzyme purified from [http://en.wikipedia.org/wiki/Sus_scrofa ''sus scrofa''] is shown in complex with the inhibitor '''[http://en.wikipedia.org/wiki/Carbidopa ''carbidopa'']''' to the right.
[[image:dopa.png|thumb|left|300px|'''Dopamine Synthesis''']]'''DOPA decarboxylase''' (DDC, aromatic L-amino acid decarboxylase, tryptophan decarboxylase, 5-hydroxytryptophan decarboxylase, AAAD) ([[EC Number|EC]] 4.1.1.28) is an approximately 104 kDa protein that belongs to the '''aspartate aminotransferase family''' (fold type 1) of '''[http://en.wikipedia.org/wiki/Pyridoxal_phosphate ''PLP'']-dependent''' (vitamin B6-dependent) enzymes. The catalytically active form of the enzyme exists as a homodimer, typical of this class of enzymes.<ref name="schneider">PMID:10673430 </ref> The homodimeric form of the enzyme purified from [http://en.wikipedia.org/wiki/Sus_scrofa ''sus scrofa''] is shown in complex with the inhibitor '''[http://en.wikipedia.org/wiki/Carbidopa ''carbidopa'']''' to the right.
-
DDC catalyzes the conversion of aromatic amino acids into their corresponding amines. DOPA decarboxylase is responsible for the synthesis of '''[http://en.wikipedia.org/wiki/Dopamine ''dopamine'']''' and [http://en.wikipedia.org/wiki/Serotoninn ''serotonin''] from '''[http://en.wikipedia.org/wiki/L-dopa ''L-DOPA'']''' and [http://en.wikipedia.org/wiki/L-5-Hydroxytryptophan ''L-5-hydroxytryptophan''], respectively. It is highly stereospecific, yet relatively nonspecific in terms of substrate, making it a somewhat uninteresting enzyme to study. Although it is not typically a rate-determining step of dopamine synthesis, the decarboxylation of L-DOPA to dopamine by DDC is the controlling step for individuals with '''[http://en.wikipedia.org/wiki/Parkinson%27s_disease ''Parkinson's disease'']'''<ref name="hadjiiconstantinou">PMID:1904055 </ref> , the second most common neurodegenerative disorder, occuring in 1% of the population over the age of 65. The loss of dopaminergic neurons is the main cause of cognitive impairment and tremors observed in patients with the disease. The hallmark of the disease is the formation of [http://en.wikipedia.org/wiki/alpha-synuclein ''alpha-synuclein''] containing [http://en.wikipedia.org/wiki/Lewy body ''Lewy bodies''].
+
DDC catalyzes the conversion of aromatic amino acids into their corresponding amines. DOPA decarboxylase is responsible for the synthesis of '''[http://en.wikipedia.org/wiki/Dopamine ''dopamine'']''' and [http://en.wikipedia.org/wiki/Serotoninn ''serotonin''] from '''[http://en.wikipedia.org/wiki/L-dopa ''L-DOPA'']''' and [http://en.wikipedia.org/wiki/L-5-Hydroxytryptophan ''L-5-hydroxytryptophan''], respectively. It is highly stereospecific, yet relatively nonspecific in terms of substrate, making it a somewhat uninteresting enzyme to study. Although it is not typically a rate-determining step of dopamine synthesis, the decarboxylation of L-DOPA to dopamine by DDC is the controlling step for individuals with '''[http://en.wikipedia.org/wiki/Parkinson%27s_disease ''Parkinson's disease'']'''<ref name="hadjiiconstantinou">PMID:1904055 </ref> , the second most common neurodegenerative disorder, occuring in 1% of the population over the age of 65. The loss of dopaminergic neurons is the main cause of cognitive impairment and tremors observed in patients with the disease. The hallmark of the disease is the formation of [http://en.wikipedia.org/wiki/alpha-synuclein ''alpha-synuclein''] containing [http://en.wikipedia.org/wiki/Lewy_body ''Lewy bodies''].
Currently, treatment for the disease is aimed at DOPA decarboxylase inhibition. Since dopamine cannot cross the blood-brain barrier, it cannot be used to directly treat Parkinson's disease. Thus, exogenously administered L-DOPA is the primary treatment for patients suffering from this neurodegenerative disease. Unfortunately, DOPA decarboxylase rapidly converts L-DOPA to dopamine in the blood stream, with only a small percentage reaching the brain. By inhibiting the enzyme, greater amounts of exogenously administered L-DOPA can reach the brain, where it can then be converted to dopamine. <ref name="burkhard">PMID:11685243 </ref> . See also [[DOPA Decarboxylase]] and [[User:Brian Hernandez/DOPA Decarboxylase]]. Unfortunately, with continued L-Dopa treatment, up to 80% of patients experience 'wearing-off' symptoms, dyskinesias and other motor complications (referred to as the "on-off phenomenon". <ref name="lees">PMID:1904055 </ref>. Clearly, a better understanding of the catalytic mechanism and enzymatic activity of DDC in both healthy and PD individuals is critical to drug design and treatment of the disease.
Currently, treatment for the disease is aimed at DOPA decarboxylase inhibition. Since dopamine cannot cross the blood-brain barrier, it cannot be used to directly treat Parkinson's disease. Thus, exogenously administered L-DOPA is the primary treatment for patients suffering from this neurodegenerative disease. Unfortunately, DOPA decarboxylase rapidly converts L-DOPA to dopamine in the blood stream, with only a small percentage reaching the brain. By inhibiting the enzyme, greater amounts of exogenously administered L-DOPA can reach the brain, where it can then be converted to dopamine. <ref name="burkhard">PMID:11685243 </ref> . See also [[DOPA Decarboxylase]] and [[User:Brian Hernandez/DOPA Decarboxylase]]. Unfortunately, with continued L-Dopa treatment, up to 80% of patients experience 'wearing-off' symptoms, dyskinesias and other motor complications (referred to as the "on-off phenomenon". <ref name="lees">PMID:1904055 </ref>. Clearly, a better understanding of the catalytic mechanism and enzymatic activity of DDC in both healthy and PD individuals is critical to drug design and treatment of the disease.
Line 8: Line 8:
----
----
===Overview===
===Overview===
-
Pyridoxal-5'-phosphate (PLP), the biologically active phosphorylated derivative of vitamin B6, is a versatile and abundant cofactor to a variety of enzymes in all organisms. Almost all PLP-dependet enzymes function in pathways associated with amino compounds, primarily amino acid metabolism. These enzymes carry out many types of reactions, including transaminations, '''decarboxylations''', racemizations, and deaminations (amongst others). PLP is considered to be the most versatile cofactor, thus imparting a wide range of functions on PLP-dependent enzymes. This versatility stems from the fact that PLP can covalently bind the substrate and then act as an electrophilic catalyst. And although these enzymes have wide range of function, there exist only '''five structural classes:''' the '''aspartate amino transferase family''', the tryptophan synthase β family, the alanine racemase family, the D-amino acid family, and the glycogen phosphorylase family. <ref name="percudani">PMID:12949584 </ref> <ref name="schneider">PMID:10673430 </ref> [[image:plp6.jpg|thumb|center|600px|'''The PLP is bound covalently to lysine residues in a Schiff base linkage (aldimine). In this form, it reacts with many free amino acids to replace the Schiff base to the lysine of the enzyme with a Schiff base to the amino acid substrate.'']]
+
Pyridoxal-5'-phosphate (PLP) is the biologically active phosphorylated derivative of vitamin B6. PLP-dependent enzymes are functionally diverse, with 150+ distinct activities, including transiminations, '''decarboxylations''', racemizations, and deaminations. With few exceptions, all PLP-dependent enzymes participate in amino acid metabolism. The versatility of PLP-dependent enzymes is, in large part, due to two basic chemical properties of the coenzyme. First, it can form a covalent bond with the substrate via its aldehyde group. Second, it can act as an electrophilic catalyst, serving as an electron sink which stabilizes the obligatory carbanionic intermediates formed during the reaction.
 +
The uniqueness and exclusivity of each enzyme’s active site are what impart specificity on the reaction type
 +
Although these enzymes have wide range of function, there exist only '''five structural classes:''' the '''aspartate amino transferase family''', the tryptophan synthase β family, the alanine racemase family, the D-amino acid family, and the glycogen phosphorylase family. <ref name="percudani">PMID:12949584 </ref> <ref name="schneider">PMID:10673430 </ref> [[image:plp6.jpg|thumb|center|600px|'''The PLP is bound covalently to lysine residues in a Schiff base linkage (aldimine). In this form, it reacts with many free amino acids to replace the Schiff base to the lysine of the enzyme with a Schiff base to the amino acid substrate.'']]
----
----
===The Aspartate Aminotransferase Family===
===The Aspartate Aminotransferase Family===

Revision as of 15:35, 30 April 2012

Pig DOPA decarboxylase complex with inhibitor carbidopa, vitamin B6 phosphate and sulfate, 1js3

Drag the structure with the mouse to rotate

3D structures of DOPA decarboxylase

Update November 2011

3k40 – DDC – Drosophila melanogaster
1js3 – pDDC + inhibitor – pig
1js6 - pDDC
3rbf, 3rbl – hDDC – human
3rch – hDDC + vitamin B6 phosphate + pyridoxal phosphate

References


  1. 1.0 1.1 Schneider G, Kack H, Lindqvist Y. The manifold of vitamin B6 dependent enzymes. Structure. 2000 Jan 15;8(1):R1-6. PMID:10673430
  2. Miles EW. The tryptophan synthase alpha 2 beta 2 complex. Cleavage of a flexible loop in the alpha subunit alters allosteric properties. J Biol Chem. 1991 Jun 15;266(17):10715-8. PMID:1904055
  3. Burkhard P, Dominici P, Borri-Voltattorni C, Jansonius JN, Malashkevich VN. Structural insight into Parkinson's disease treatment from drug-inhibited DOPA decarboxylase. Nat Struct Biol. 2001 Nov;8(11):963-7. PMID:11685243 doi:http://dx.doi.org/10.1038/nsb1101-963
  4. Miles EW. The tryptophan synthase alpha 2 beta 2 complex. Cleavage of a flexible loop in the alpha subunit alters allosteric properties. J Biol Chem. 1991 Jun 15;266(17):10715-8. PMID:1904055
  5. Percudani R, Peracchi A. A genomic overview of pyridoxal-phosphate-dependent enzymes. EMBO Rep. 2003 Sep;4(9):850-4. PMID:12949584 doi:http://dx.doi.org/10.1038/sj.embor.embor914
  6. Aurora R, Rose GD. Helix capping. Protein Sci. 1998 Jan;7(1):21-38. PMID:9514257 doi:10.1002/pro.5560070103
  7. Jansonius JN. Structure, evolution and action of vitamin B6-dependent enzymes. Curr Opin Struct Biol. 1998 Dec;8(6):759-69. PMID:9914259
  8. 8.0 8.1 Ishii S, Mizuguchi H, Nishino J, Hayashi H, Kagamiyama H. Functionally important residues of aromatic L-amino acid decarboxylase probed by sequence alignment and site-directed mutagenesis. J Biochem. 1996 Aug;120(2):369-76. PMID:8889823
Personal tools